University Hospital of Düsseldorf, Departments for Neurology and Neurosurgery
Welcome,         Profile    Billing    Logout  
 3 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schnitzler, Alfons
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed
3
523
Europe, US
buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo
Annovis Bio Inc., TFS Trial Form Support
Parkinson's Disease, Idiopathic
12/23
12/23
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed
3
507
Europe, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
01/24
02/24
TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)

Completed
3
522
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
06/24
06/24
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
PROSPER, NCT06355531: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

Recruiting
2
220
Europe, US
FNP-223, Placebo
Ferrer Internacional S.A.
Progressive Supranuclear Palsy
11/26
11/26
LUMA, NCT05348785 / 2021-004849-20: A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

Recruiting
2
640
Europe, Canada, Japan, US, RoW
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
12/25
12/25
ROAM-DBS, NCT05269862: Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation

Active, not recruiting
N/A
100
Europe, US
Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature, Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)
Abbott Medical Devices
Parkinson Disease
12/23
12/24
NCT06498349: Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl

Recruiting
N/A
60
Europe
bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment, best medical treatment for management of impulse control in Parkinson´s disease, best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations
University of Kiel, Insel Gruppe AG, University Hospital Bern, Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC), Philipps University Marburg Medical Center, University Hospital Schleswig-Holstein, Campus Kiel, Czech Technical University in Prague, University of Pennsylvania
Parkinson Disease, Impulse Control Disorders
07/27
07/28
NCT06561919: STIMPulseControl Ancillary Speech Study

Recruiting
N/A
60
Europe
bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper, best medical treatment for manangement of impulse control in Parkinson´s disease, best medical treatment for management of impulse control in Parkinson´s disease according to widely accepted expert consensus paper
Steffen Paschen, Czech Technical University in Prague, Insel Gruppe AG, University Hospital Bern, Philipps University Marburg Medical Center, University Hospital Schleswig-Holstein, Campus Kiel, Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
Parkinson Disease, Impulse Control Disorder
07/27
07/28
NCT05363046: Noninterventional Study Evaluating Parkinson's Disease Diary Use

Active, not recruiting
N/A
194
Europe, Canada, US
BlueRock Therapeutics
Parkinson's Disease
10/25
10/26
ADROIT, NCT04071847: Abbott DBS Post-Market Study of Outcomes for Indications Over Time

Recruiting
N/A
1000
Europe, US, RoW
Deep Brain Stimulation (DBS)
Abbott Medical Devices
Movement Disorders, Parkinson Disease, Essential Tremor, Tremor, Dystonia, Primary Dystonia, Secondary Dystonia
09/29
09/30

Download Options